---
title: "Hematology"
order: 4
category: "Internal Medicine"
---

# Hematology

## Overview

Hematology is the medical specialty focused on the diagnosis and treatment of disorders affecting blood and blood-forming organs, including bone marrow, red blood cells, white blood cells, platelets, and the coagulation system. Hematologic disorders range from common nutritional anemias to life-threatening malignancies like leukemia and lymphoma. Understanding hematology is essential for all physicians, as blood abnormalities are frequently encountered in clinical practice.

### Scope of Hematology
- **Red blood cell disorders**: Anemia (iron deficiency, megaloblastic, hemolytic), polycythemia
- **White blood cell disorders**: Leukopenia, neutropenia, leukocytosis
- **Platelet disorders**: Thrombocytopenia, thrombocytosis, platelet dysfunction
- **Coagulation disorders**: Hemophilia, von Willebrand disease, DIC, thrombophilia
- **Hematologic malignancies**: Leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes
- **Bone marrow disorders**: Aplastic anemia, myelofibrosis, myeloproliferative neoplasms
- **Transfusion medicine**: Blood product administration, transfusion reactions

### Epidemiology
- Anemia: Affects 1.62 billion people globally (WHO)
- Iron deficiency: Most common cause of anemia worldwide
- Sickle cell disease: 100,000 Americans, predominantly African Americans
- Hemophilia A: 1 in 5,000 male births
- Acute leukemia: 20,000 new cases annually in US
- Non-Hodgkin lymphoma: 80,000 new cases annually in US
- Venous thromboembolism: 900,000 cases annually in US

## Hematopoiesis

### Overview

Hematopoiesis is the process of blood cell formation occurring primarily in the bone marrow. All blood cells originate from hematopoietic stem cells that differentiate into distinct lineages.

### Hematopoietic Stem Cells

- Pluripotent stem cells in bone marrow
- Self-renewal capacity
- Differentiate into all blood cell types
- Regulated by growth factors and cytokines

### Cell Lineages

**Myeloid lineage**:
- Erythrocytes (red blood cells)
- Megakaryocytes → platelets
- Granulocytes: Neutrophils, eosinophils, basophils
- Monocytes → macrophages

**Lymphoid lineage**:
- T lymphocytes
- B lymphocytes → plasma cells
- Natural killer (NK) cells

### Growth Factors and Regulation

- **Erythropoietin (EPO)**: Stimulates red blood cell production (kidneys)
- **Granulocyte colony-stimulating factor (G-CSF)**: Stimulates neutrophil production
- **Thrombopoietin (TPO)**: Stimulates platelet production
- **Interleukins**: Various roles in lymphocyte development

## Diagnostic Approaches

### Complete Blood Count (CBC)

**Red blood cell parameters**:
- **Hemoglobin** (Hgb): Oxygen-carrying protein
  - Normal: Men 13.5-17.5 g/dL, Women 12-15.5 g/dL
- **Hematocrit** (Hct): Percentage of blood volume that is RBCs
  - Normal: Men 40-50%, Women 36-44%
- **MCV** (Mean corpuscular volume): Average RBC size
  - Normal: 80-100 fL
  - Microcytic: <80 fL
  - Macrocytic: >100 fL
- **MCH and MCHC**: Hemoglobin content and concentration
- **RDW** (Red cell distribution width): Variation in RBC size
  - Elevated in mixed deficiencies

**White blood cell count**:
- Total WBC: Normal 4,500-11,000/μL
- **Differential**:
  - Neutrophils: 40-70% (2,000-7,000/μL)
  - Lymphocytes: 20-40% (1,000-4,000/μL)
  - Monocytes: 2-8% (100-800/μL)
  - Eosinophils: 1-4% (50-400/μL)
  - Basophils: 0-1% (25-100/μL)

**Platelet count**:
- Normal: 150,000-400,000/μL
- Thrombocytopenia: <150,000/μL
- Thrombocytosis: >400,000/μL

### Peripheral Blood Smear

**Indications**:
- Abnormal CBC values
- Suspected hemolysis
- Suspected hematologic malignancy
- Unexplained cytopenias

**Red blood cell morphology**:
- **Microcytic hypochromic**: Iron deficiency, thalassemia
- **Macrocytic**: Megaloblastic anemia, liver disease, alcohol
- **Schistocytes** (fragmented RBCs): Microangiopathic hemolytic anemia (MAHA), TTP, DIC
- **Spherocytes**: Hereditary spherocytosis, immune hemolytic anemia
- **Target cells**: Thalassemia, liver disease, hemoglobin C
- **Sickle cells**: Sickle cell disease
- **Howell-Jolly bodies**: Asplenia
- **Basophilic stippling**: Lead poisoning, thalassemia

**White blood cell morphology**:
- **Blasts**: Acute leukemia
- **Atypical lymphocytes**: Viral infection (EBV, CMV)
- **Toxic granulation**: Bacterial infection
- **Döhle bodies**: Infection, inflammation

**Platelet morphology**:
- **Large platelets**: ITP, myeloproliferative disorders
- **Small platelets**: Wiskott-Aldrich syndrome

### Bone Marrow Examination

**Indications**:
- Unexplained cytopenias
- Suspected hematologic malignancy
- Staging lymphoma, myeloma
- Evaluation of iron stores
- Fever of unknown origin

**Procedures**:
- **Bone marrow aspiration**: Liquid sample for cytology, flow cytometry
- **Bone marrow biopsy**: Core sample for histology, architecture
- Usually from posterior iliac crest

**Analysis**:
- Cellularity (normal 40-60% in adults, decreases with age)
- Myeloid:erythroid ratio (normal 3:1)
- Blast percentage
- Megakaryocyte number and morphology
- Iron stores (Prussian blue stain)
- Flow cytometry for immunophenotyping
- Cytogenetics and molecular studies

### Coagulation Studies

**Screening tests**:
- **PT (prothrombin time)**: Extrinsic pathway (factors VII, X, V, II, fibrinogen)
  - Normal: 11-13 seconds
  - INR (international normalized ratio): 0.8-1.2
- **aPTT (activated partial thromboplastin time)**: Intrinsic pathway (factors XII, XI, IX, VIII, X, V, II, fibrinogen)
  - Normal: 25-35 seconds
- **Thrombin time**: Fibrinogen to fibrin conversion
- **Fibrinogen**: Normal 200-400 mg/dL

**Platelet function**:
- **Bleeding time**: Historical, rarely used
- **PFA-100**: Platelet function analyzer
- **Platelet aggregation studies**: Response to various agonists

**Specific factor assays**:
- Factor VIII, IX levels (hemophilia)
- Von Willebrand factor antigen and activity

**Hypercoagulability workup**:
- Protein C, protein S, antithrombin III
- Factor V Leiden mutation
- Prothrombin G20210A mutation
- Lupus anticoagulant, anticardiolipin, anti-β2-glycoprotein I antibodies
- Homocysteine

## Common Hematologic Disorders

### Anemia
- Iron deficiency anemia
- Anemia of chronic disease
- Megaloblastic anemia (B12, folate deficiency)
- Hemolytic anemias (immune, hereditary spherocytosis, G6PD deficiency, sickle cell disease)
- Aplastic anemia

### Coagulation Disorders
- Hemophilia A and B
- Von Willebrand disease
- Disseminated intravascular coagulation (DIC)
- Thrombophilias (Factor V Leiden, prothrombin mutation, protein C/S deficiency)
- Antiphospholipid syndrome

### Leukemia
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic lymphocytic leukemia (CLL)
- Chronic myeloid leukemia (CML)

### Lymphoma
- Hodgkin lymphoma
- Non-Hodgkin lymphoma (diffuse large B-cell, follicular, mantle cell, etc.)

### Myeloproliferative Neoplasms
- Polycythemia vera
- Essential thrombocythemia
- Primary myelofibrosis

### Plasma Cell Disorders
- Multiple myeloma
- Monoclonal gammopathy of undetermined significance (MGUS)
- Waldenström macroglobulinemia

### Platelet Disorders
- Immune thrombocytopenic purpura (ITP)
- Thrombotic thrombocytopenic purpura (TTP)
- Heparin-induced thrombocytopenia (HIT)

## Treatment Principles

### Transfusion Therapy

**Packed red blood cells (PRBCs)**:
- Indications: Symptomatic anemia, Hgb <7 g/dL (liberal threshold <10 g/dL if cardiac disease, active bleeding)
- One unit raises Hgb by ~1 g/dL
- ABO and Rh compatible

**Platelets**:
- Indications: Platelet count <10,000/μL (prophylactic), <50,000/μL with bleeding or pre-procedure
- One unit raises platelet count by 5,000-10,000/μL
- ABO compatible preferred, Rh not critical

**Fresh frozen plasma (FFP)**:
- Indications: Coagulation factor deficiency, warfarin reversal, TTP (plasma exchange)
- Contains all clotting factors
- ABO compatible

**Cryoprecipitate**:
- Rich in fibrinogen, factor VIII, vWF, factor XIII
- Indications: Hypofibrinogenemia (DIC), hemophilia A, vWD

**Transfusion reactions**:
- Acute hemolytic: ABO incompatibility, immediate, life-threatening
- Febrile non-hemolytic: Most common, cytokine-mediated
- Allergic: Urticaria, anaphylaxis
- TRALI (transfusion-related acute lung injury): Respiratory distress within 6 hours
- TACO (transfusion-associated circulatory overload): Volume overload

### Hematopoietic Growth Factors

- **Erythropoiesis-stimulating agents (ESAs)**: Epoetin alfa, darbepoetin (for anemia of CKD, chemotherapy)
- **G-CSF**: Filgrastim, pegfilgrastim (for chemotherapy-induced neutropenia)
- **Thrombopoietin receptor agonists**: Romiplostim, eltrombopag (for ITP)

### Anticoagulation

**Heparin**:
- Unfractionated heparin (UFH): IV, monitor aPTT
- Low molecular weight heparin (LMWH): Enoxaparin, dalteparin (SC, predictable dosing)

**Vitamin K antagonist**:
- Warfarin: Monitor INR, target 2-3 (most indications) or 2.5-3.5 (mechanical valves)

**Direct oral anticoagulants (DOACs)**:
- Factor Xa inhibitors: Rivaroxaban, apixaban, edoxaban
- Direct thrombin inhibitor: Dabigatran
- No routine monitoring, fewer drug interactions than warfarin

**Indications**:
- Venous thromboembolism (DVT, PE)
- Atrial fibrillation (stroke prevention)
- Mechanical heart valves (warfarin only)

### Chemotherapy

- Used for hematologic malignancies
- Cytotoxic agents, targeted therapies, immunotherapy
- Discussed in oncology section

### Hematopoietic Stem Cell Transplantation

**Autologous**:
- Patient's own stem cells
- High-dose chemotherapy followed by stem cell rescue
- Indications: Lymphoma, myeloma

**Allogeneic**:
- Donor stem cells (matched sibling, unrelated donor)
- Graft-versus-tumor effect
- Risk of graft-versus-host disease (GVHD)
- Indications: Acute leukemia, aplastic anemia, sickle cell disease

## Key Points

- Hematology encompasses disorders of red blood cells, white blood cells, platelets, coagulation, and hematologic malignancies
- CBC with differential and peripheral blood smear are fundamental diagnostic tools for evaluating hematologic abnormalities
- Anemia is classified by MCV: Microcytic (iron deficiency, thalassemia), normocytic (chronic disease, hemolysis), macrocytic (B12/folate deficiency)
- Coagulation studies (PT, aPTT) evaluate intrinsic and extrinsic pathways; specific factor assays diagnose hemophilia and vWD
- Hematologic malignancies require bone marrow examination, flow cytometry, cytogenetics, and molecular studies for diagnosis and classification
- Transfusion therapy follows specific indications and thresholds; recognize and manage transfusion reactions promptly
- Anticoagulation options include heparin, warfarin, and DOACs; choice depends on indication, patient factors, and monitoring capability

## References

1. Hoffman R, Benz EJ Jr, Silberstein LE, et al. Hematology: Basic Principles and Practice. 7th ed. Elsevier; 2018.

2. Kaushansky K, Lichtman MA, Prchal JT, et al. Williams Hematology. 9th ed. McGraw-Hill Education; 2015.

3. Camaschella C. Iron-Deficiency Anemia. N Engl J Med. 2015;372(19):1832-1843.

4. Stabler SP. Vitamin B12 Deficiency. N Engl J Med. 2013;368(2):149-160.

5. Slichter SJ. Evidence-Based Platelet Transfusion Guidelines. Hematology Am Soc Hematol Educ Program. 2007:172-178.

6. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352.

7. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S-e43S.

8. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136-1152.

9. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. IARC; 2017.

10. Tefferi A, Barbui T. Polycythemia Vera and Essential Thrombocythemia: 2021 Update on Diagnosis, Risk-Stratification and Management. Am J Hematol. 2020;95(12):1599-1613.
